September 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.
July 2022 in “International Journal of Trichology” Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.
April 2021 in “Journal of Investigative Dermatology” Leontopodium alpinum extract may help reduce hair shedding by keeping hair in the growth phase longer.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
1 citations
,
January 2024 in “Pharmaceuticals” A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
1 citations
,
November 2021 in “IntechOpen eBooks” Red light therapy may help prevent memory loss as we age.
August 2022 in “IntechOpen eBooks” The best treatment for Frontal Fibrosing Alopecia and Lichen Planopilaris combines oral and topical medications to reduce symptoms and stop hair loss.
2 citations
,
January 2002 in “Dermatology + psychosomatics” Topiramate may cause reversible hair loss.
18 citations
,
March 2004 in “Clinics in Dermatology” Lupus can cause hair loss and nail changes, with treatments available for both.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
June 2021 in “bioRxiv (Cold Spring Harbor Laboratory)” Gene therapy in mice increased lifespan and improved health without causing cancer.
17 citations
,
April 1997 in “Archives of dermatology” The document describes a treatment for excessive hair growth in a teenage girl using medication and birth control, but does not report the results.
March 2026 in “International Journal of Dermatology Venereology and Leprosy Sciences” Vitiligo treatment requires a personalized mix of therapies to restore skin color and improve life quality.
1 citations
,
June 2017 in “Skin” Apremilast may help treat lichen planopilaris and frontal fibrosing alopecia when other treatments fail.
124 citations
,
April 2000 in “Nature biotechnology” 9 citations
,
November 2021 in “PubMed” FDA-approved low-level light/laser therapy devices can significantly increase hair density in people with pattern hair loss.
May 2024 in “Pigment International” Several treatments are effective for pigmentary disorders like vitiligo and melasma.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.
11 citations
,
February 2012 in “Pediatrics in Review” Early and aggressive treatment with individualized care plans is crucial for managing pediatric systemic lupus erythematosus.
May 2025 in “International Journal of Trichology” The supplement improved hair health and reduced shedding in people with telogen effluvium.
January 2024 in “International journal of molecular sciences” A brain-made hormone can protect against memory-related brain damage caused by harmful proteins.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
July 2023 in “Indian Journal of Endocrinology and Metabolism” An 11-year-old girl's hair regrew after treating her thyroid condition with carbimazole.
April 2016 in “Journal of Investigative Dermatology” Blocking certain proteins can significantly regrow hair in severe alopecia areata.
15 citations
,
January 2024 in “The AAPS Journal” 50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
June 2026 in “Frontiers in Nutrition” The document discusses the use of GLP-1 receptor agonists (GLP-1RAs) in managing Polycystic Ovary Syndrome (PCOS), focusing on their metabolic benefits rather than confirmed fertility enhancement. The narrative synthesis highlights the need for individualized treatment plans, emphasizing the distinction between metabolic optimization and reproductive outcomes. The study suggests GLP-1RAs should be used as short-term, preconception tools, with careful planning for drug discontinuation to avoid rebound effects. The authors call for future trials to standardize reproductive endpoints and capture periconception exposure to better assess the benefits and risks.
9 citations
,
July 2017 in “Journal of medical case reports” Ruxolitinib treatment may cause eyelash growth.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.